Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort | Synapse
January 25, 2026Journal of Dermatological Treatment0 citationsOpen Access
Risankizumab super responders in moderate-to-severe psoriasis: prevalence, predictors, and long-term maintenance in a multicenter, international, real-world cohort
The goal is to identify the prevalence and factors predicting high effectiveness of risankizumab in psoriasis patients, as well as evaluate its long-term maintenance.
Multi-center international cohort
Real-world data collection
Assessment of treatment outcomes and predictors
High prevalence of super responders identified
Sustained long-term clearance achieved in many patients
Several predictors for effectiveness established
Abstract
Risankizumab demonstrated high and sustained long-term effectiveness, inducing rapid and sustained complete clearance in a substantial proportion of patients.